Tirzepatide is a first-in-class dual GLP-1 and GIP receptor agonist approved for type 2 diabetes (as Mounjaro) and obesity (as Zepbound). It's a weekly injection that improves blood sugar control and produces significant weight loss by activating two incretin hormone receptors.

How does tirzepatide compare to semaglutide?

Head-to-head trials show tirzepatide produces greater weight loss (12.4kg vs 6.2kg) and better glucose control than semaglutide 1mg. At maximum doses, tirzepatide achieves ~22% weight loss vs ~17% for semaglutide. However, semaglutide has more cardiovascular outcomes data.

Is tirzepatide approved in the UK?

Yes. Mounjaro (tirzepatide for diabetes) received MHRA approval in 2023. Zepbound (for weight management) approval is pending or recently approved. Both are prescription-only medicines requiring medical supervision.

What are the side effects of tirzepatide?

Common side effects include nausea, diarrhoea, vomiting, and constipation—though these may be somewhat milder than pure GLP-1 agonists. Hair loss has been reported in weight loss trials, likely due to rapid weight loss. Rare risks include pancreatitis and gallbladder problems.

How much weight can I lose on tirzepatide?

Clinical trials show average weight loss of 20-22% at the highest doses (15mg). About 63% of participants lost 20% or more of their body weight. Results vary individually and depend on dose, adherence, diet, and physical activity.

Can I buy tirzepatide without a prescription?

No. Tirzepatide is a prescription-only medicine. Purchasing from unregulated sources is dangerous and may result in counterfeit, contaminated, or incorrectly dosed products. Always obtain through legitimate healthcare providers.

What is the difference between Mounjaro and Zepbound?

Both contain tirzepatide. Mounjaro is approved for type 2 diabetes, while Zepbound is approved specifically for weight management. The medication is identical; the difference is the approved indication and potentially insurance coverage.

Are tirzepatide vials sold as research peptides the same as Mounjaro?

No. Tirzepatide is a prescription-only medicine and is not a research peptide. There is no licensed generic: 'generic tirzepatide' is grey-market product without regulatory provenance, and vials labelled 'tirzepatide' sold for 'research' sit outside the regulated supply chain.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 25 September 2026

Corrected 25 September 2026: The SURMOUNT-4 study summary said patients switched to placebo regained "approximately half" the lost weight. Per the trial abstract (Aronne et al., JAMA 2024), the 36-week lead-in produced 20.9% mean weight loss, and the placebo arm regained a mean of 14.0% by week 88 — around two-thirds of the lead-in loss. The summary has been rewritten to match.

Share:X Post LinkedIn

GLP-1 Agonists•Updated 2026-09-25•7 min read

What Is Tirzepatide? Benefits, Research & Safety

Q: Why does tirzepatide cause more weight loss than semaglutide?

Tirzepatide activates both GIP and GLP-1 receptors, while semaglutide only activates GLP-1. The dual mechanism appears to produce synergistic effects on appetite suppression and metabolism. The exact mechanisms are still being researched.

A first-in-class dual GLP-1 and GIP receptor agonist achieving unprecedented weight loss of up to 22% in clinical trials, approved for type 2 diabetes and obesity treatment.

Share:X Post LinkedIn

Also known as:

Mounjaro

Zepbound

LY3298176

AStrong human evidenceUK: Prescription-only (UK POM)WADA: Sport status unclear

UK summary: Licensed UK medicine (Mounjaro). Dual GLP-1 / GIP receptor agonist. Prescription-only. NHS access depends on NICE guidance and local commissioning. Counterfeit pens and unregulated 'research only' vials are a UK safety concern.

Is tirzepatide a peptide, and what is its status in the UK?

Tirzepatide is a 39-amino acid peptide that activates both the GIP and GLP-1 receptors, marketed in the UK as Mounjaro. It is a prescription-only medicine, not a research peptide, and should only be obtained through legitimate healthcare channels.

What are the key facts about Tirzepatide?

What it is: Dual GLP-1 and GIP receptor agonist (39-amino acid peptide)
Brand names: Mounjaro, Zepbound
UK status: Prescription-only. NHS access depends on NICE guidance and local commissioning.
Licensed generic: None. 'Generic tirzepatide' is grey-market product without regulatory provenance.
Administration: Once weekly subcutaneous injection
Half-life: Approximately 5 days (120 hours)
SURMOUNT-1 (obesity without diabetes; 15mg, 72 weeks): 22.5% mean weight loss vs 2.4% placebo
SURPASS-2 (type 2 diabetes; tirzepatide 15mg vs semaglutide 1mg): HbA1c reduction 2.46% vs 1.86%; weight loss 12.4kg vs 6.2kg

Quick Facts

Overview

Tirzepatide represents the next evolution in incretin-based therapies, being the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist to achieve regulatory approval. Developed by Eli Lilly, it is marketed as Mounjaro® (for diabetes) and Zepbound® (for weight management). By activating both GIP and GLP-1 receptors, tirzepatide produces greater metabolic effects than GLP-1 agonists alone. The SURMOUNT trials demonstrated unprecedented weight loss of up to 22.5%—results approaching those of bariatric surgery without surgical intervention. The molecule consists of a 39-amino acid peptide engineered to activate both incretin receptors. A fatty acid modification enables once-weekly dosing, similar to semaglutide. The dual mechanism appears to produce synergistic effects on glucose control, appetite suppression, and body composition. Tirzepatide has been described as a paradigm shift in obesity treatment, prompting discussions about obesity as a treatable chronic disease rather than a lifestyle failure. Its success has accelerated development of even more potent multi-agonist compounds. **Regulatory Status:** Tirzepatide is a prescription-only medicine approved by the FDA and EMA. It should only be obtained through legitimate healthcare channels.

Evidence standards summary

Tirzepatide — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

AStrong human evidenceOverall grade against our evidence grading methodology.

Licensed UK medicine (Mounjaro). Dual GLP-1 / GIP receptor agonist. Prescription-only. NHS access depends on NICE guidance and local commissioning. Counterfeit pens and unregulated 'research only' vials are a UK safety concern.

02Human evidence grade

AStrong human evidenceStrength of evidence from published human trials.

03Preclinical evidence grade

AStrong human evidenceAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: Mounjaro approved by MHRA for type 2 diabetes (2023). Zepbound for weight management under review/approved. Prescription-only medicine.
EU: Mounjaro approved by EMA (September 2022) for type 2 diabetes. Weight management approval ongoing.
Notes: Tirzepatide is a prescription-only medication. It is NOT a research peptide and should only be obtained through legitimate healthcare channels. Counterfeit products are a significant concern—only use verified pharmacies.

05Approved medical uses

Mounjaro — UK weight management (NICE TA1026)
Mounjaro — UK type 2 diabetes

06Unapproved / promotional claims

Safe at any BMI without specialist input
Compounded tirzepatide is equivalent to Mounjaro
Best-in-class regardless of individual tolerability or comorbidities

07Common internet claims

Up to 22% weight loss is a guarantee for everyone
Skip the NHS waiting list — buy online instead
Combine Mounjaro with research peptides for ‘maximum effect’

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Produces ~20% weight loss in eligible patients”	A	Yes	Low	SURMOUNT trials show mean weight loss in the high teens to low twenties (%) at maximum dose; individual results vary.
“Better than semaglutide for everyone”	B	Yes	Low	Head-to-head data suggest greater weight loss on average, but individual factors and side-effect tolerance matter — a prescriber decision.
“Generic 'tirzepatide' is the same as Mounjaro”	E	No	High	There is no licensed generic. 'Generic tirzepatide' is grey-market product without regulatory provenance.
“Compounded tirzepatide is a legal workaround”	E	No	High	UK compounding rules are narrow. Most 'compounded GLP-1' offers are not legitimate compounded medicine.

09Safety uncertainty score

Moderate

Safety profile partly characterised; some signals from observational or preclinical data.

10Known adverse signals

Nausea, vomiting, diarrhoea, constipation (common, dose-dependent)
Gallbladder disease — class effect
Pancreatitis — uncommon, recognised
Hypoglycaemia in combination with insulin or sulfonylureas
Contraindicated in pregnancy and breastfeeding
February 2026 MHRA alert: falsified 15 mg KwikPens via unlicensed supply

11Drug-interaction uncertainty

Low

Drug-interaction picture documented in the prescribing information.

12Anti-doping status

WADA: Sport status unclearWADA strict-liability framing applies.

13UK legal position

UK: Prescription-only (UK POM)

Mounjaro approved by MHRA for type 2 diabetes (2023). Zepbound for weight management under review/approved. Prescription-only medicine.

Read the full UK legal guide → Tirzepatide and UK law

14EU legal position

Mounjaro approved by EMA (September 2022) for type 2 diabetes. Weight management approval ongoing.

15What this page cannot tell you

Whether tirzepatide is right for your individual clinical picture.
Whether the pen you receive is genuine if obtained outside the regulated UK chain.
How long you should stay on therapy — that is a prescriber decision.
Whether NHS access in your region is currently open via primary care or only specialist services.

16Last reviewed

Last reviewed: 25 September 2026

Next review due: 25 September 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

AStrong human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

Long-term cardiovascular outcomes data continues to mature.
Optimal management of weight regain after discontinuation.
Safety / efficacy data in adolescents and older adults.
Head-to-head data versus newer agents (retatrutide, CagriSema) when those mature.

19Safer alternatives / established care pathways

Licensed Mounjaro or Wegovy via NHS specialist service or GMC-registered private prescriber.
Structured weight-management programme as first-line.
Bariatric assessment for patients meeting NICE criteria.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Am I eligible for NHS access to tirzepatide for my situation?
What is the dose-titration plan and how will side effects be monitored?
How do you confirm the product I receive is genuine Mounjaro?
What is the plan if I want to come off the medicine?
How should I report a suspected side effect?

Discovery & History

Tirzepatide's development arose from understanding that GIP and GLP-1, the two main incretin hormones, might have complementary effects when activated together. **Scientific Background:** • **GIP and GLP-1:** Both hormones are released from the gut after eating and enhance insulin secretion. However, GIP's role in obesity was initially controversial—early studies suggested GIP might promote fat storage. • **Reconsidering GIP:** Research by Eli Lilly and academic groups revealed that GIP receptor activation in the brain might reduce food intake, contrary to earlier assumptions about its fat-promoting effects. **Development Timeline:** • **2016:** Eli Lilly begins Phase 1 trials of LY3298176 • **2018:** Phase 2 results show superior efficacy to dulaglutide and semaglutide • **2020-2021:** SURPASS trials for diabetes show superior glucose control • **2021-2022:** SURMOUNT trials for obesity show unprecedented weight loss • **May 2022:** FDA approval of Mounjaro for type 2 diabetes • **September 2022:** EMA approval for Mounjaro • **November 2023:** FDA approval of Zepbound for weight management • **2024:** MHRA approval and UK availability begins The discovery that dual agonism produced greater effects than either receptor alone was somewhat surprising and has driven development of triple agonists like retatrutide.

Mechanism of Action

Tirzepatide uniquely activates two incretin receptors, producing complementary metabolic effects: **GLP-1 Receptor Activation:** Similar to semaglutide, tirzepatide activates GLP-1 receptors to: - Enhance glucose-dependent insulin secretion - Suppress glucagon release - Slow gastric emptying - Reduce appetite through hypothalamic signalling **GIP Receptor Activation:** The GIP component adds distinct benefits: - Additional insulin secretion enhancement - Potential improvements in beta cell function - Central nervous system effects on appetite (distinct from GLP-1) - Possible effects on fat metabolism and distribution **Synergistic Effects:** The dual mechanism appears to produce more than additive benefits: - Greater weight loss than GLP-1 agonists alone - Improved glucose control beyond single-agonist therapies - Potentially better tolerability (nausea may be reduced) - Enhanced effects on body composition **Molecular Design:** Tirzepatide is a 39-amino acid peptide based on the native GIP sequence but engineered to also activate GLP-1 receptors. Key features include: - C20 fatty diacid attached via linker, enabling albumin binding - Half-life of approximately 5 days allowing weekly dosing - Relative GIP:GLP-1 activation ratio of approximately 5:1 **Adipose Tissue Effects:** Emerging research suggests tirzepatide may have direct effects on fat tissue: - Improved insulin sensitivity in adipocytes - Enhanced fat oxidation - Potential preferential loss of visceral fat - Possible effects on adipokine secretion [Diagram Placeholder: Dual receptor signalling showing GIP and GLP-1 pathways, including pancreatic, central nervous system, and adipose tissue effects]

Researched Benefits

Based on preclinical and clinical research findings:

1
Weight loss of 20-22% in clinical trials—approaching bariatric surgery results
2
Superior glycaemic control with HbA1c reductions of 2.0-2.5%
3
Significant reductions in liver fat (important for NAFLD/NASH)
4
Improvements in blood pressure and lipid profiles
5
High rates of diabetes remission (HbA1c <6.5% without medication)
6
Reduced waist circumference and preferential visceral fat loss
7
Improvements in markers of inflammation
8
Better physical function and quality of life measures
9
Potential cardiovascular benefits (outcomes trials ongoing)

Claim vs Evidence

How popular claims about Tirzepatide stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Produces ~20% weight loss in eligible patients”	A	Yes	Low	SURMOUNT trials show mean weight loss in the high teens to low twenties (%) at maximum dose; individual results vary.
“Better than semaglutide for everyone”	B	Yes	Low	Head-to-head data suggest greater weight loss on average, but individual factors and side-effect tolerance matter — a prescriber decision.
“Generic 'tirzepatide' is the same as Mounjaro”	E	No	High	There is no licensed generic. 'Generic tirzepatide' is grey-market product without regulatory provenance.
“Compounded tirzepatide is a legal workaround”	E	No	High	UK compounding rules are narrow. Most 'compounded GLP-1' offers are not legitimate compounded medicine.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	Mounjaro/Zepbound: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg weekly
Frequency	Once weekly subcutaneous injection
Duration	Ongoing treatment; dose escalation over 20+ weeks
Notes	Tirzepatide is a prescription medication requiring medical supervision. Slow dose escalation is critical for tolerability. The highest doses (12.5mg, 15mg) are required for maximum weight loss but carry increased GI side effect risk. This is NOT a research peptide—obtain only through legitimate healthcare providers.

Administration Routes

Routes studied in research settings (educational only):

Subcutaneous injection (Mounjaro, Zepbound)—once weekly
Oral formulation in development

Half-Life	Stability
Approximately 5 days (120 hours)	Refrigerate at 2-8°C before first use; can be kept at room temperature (below 30°C) for up to 21 days; protect from light

Safety Profile & Known Risks

Commonly Reported Side Effects

Nausea (may be less severe than with pure GLP-1 agonists)
Diarrhoea
Vomiting
Constipation
Abdominal pain
Decreased appetite
Dyspepsia (indigestion)
Injection site reactions
Fatigue
Hair loss (reported in weight loss trials—likely related to rapid weight loss)

Rare Risks & Concerns

Pancreatitis
Gallbladder disease and gallstones
Hypoglycaemia (especially with insulin or sulfonylureas)
Acute kidney injury (secondary to dehydration)
Allergic reactions
Thyroid C-cell tumours (rodent finding; clinical significance unknown)
Intestinal obstruction (rare, in patients with GI disease)

Contraindications

Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2
Known hypersensitivity to tirzepatide
Pregnancy and breastfeeding
Type 1 diabetes
History of pancreatitis
Severe gastrointestinal disease

UK & EU Regulatory Context

🇬🇧 United Kingdom

Mounjaro approved by MHRA for type 2 diabetes (2023). Zepbound for weight management under review/approved. Prescription-only medicine.

🇪🇺 European Union

Mounjaro approved by EMA (September 2022) for type 2 diabetes. Weight management approval ongoing.

Tirzepatide is a prescription-only medication. It is NOT a research peptide and should only be obtained through legitimate healthcare channels. Counterfeit products are a significant concern—only use verified pharmacies.

Clinical Studies Summary

SURMOUNT-1: Tirzepatide for Weight Management

Landmark obesity trial showing 15mg tirzepatide produced 22.5% mean weight loss vs 2.4% placebo over 72 weeks. 63% of participants lost ≥20% body weight.

N Engl J Med. 2022View on PubMed

SURPASS-2: Tirzepatide vs Semaglutide

Head-to-head comparison showing tirzepatide 15mg superior to semaglutide 1mg for glucose control (HbA1c reduction 2.46% vs 1.86%) and weight loss (12.4kg vs 6.2kg).

N Engl J Med. 2021View on PubMed

SURMOUNT-3: After Lifestyle Intervention

Tirzepatide after initial 12-week intensive lifestyle intervention showed total weight loss of 26.6% from pre-lifestyle baseline.

Nat Med. 2023View on PubMed

SURMOUNT-4: Weight Maintenance

After a 36-week open-label tirzepatide lead-in produced 20.9% mean weight loss, continuing tirzepatide for a further 52 weeks maintained and extended weight reduction (mean change -5.5%), while switching to placebo led to a mean regain of 14.0% over that period (difference -19.4 percentage points, p<0.001) — around two-thirds of the lead-in loss.

JAMA. 2024View on PubMed

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.

Potent GLP-1 RAs, such as tirzepatide and semaglutide, demonstrate greater overall weight loss but are associated with a significant reduction in lean mass. None is related to this paper. CSM recused himself from handling this paper.

Metabolism. 2025View on PubMed

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.

In this systematic review and meta-analysis, discontinuing GLP-1RA treatment led to a pooled overall mean weight regain of 2.20 kg in participants taking liraglutide and 9.69 kg in those patients prescribed semaglutide/tirzepatide. The proportion of weight regained was proportional to the amount originally lost.

Obes Rev. 2025View on PubMed

Registered Trials & Regulatory Status

Registered trials

153

Currently recruiting

Furthest phase

Phase 4

Approved product

Yes

Zepbound, ZEPBOUND

21 of 66 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity

PHASE2

Status: Not Yet Recruiting · 40 participants · Royal North Shore Hospital

Conditions: Type 1 Diabetes Mellitus, Overweight and Obesity

No results postedNCT06180616

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

PHASE2

Status: Not Yet Recruiting · 224 participants · Biomed Industries, Inc.

Conditions: Obesity and Overweight

No results postedNCT06732245

Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF

PHASE4

Status: Not Yet Recruiting · 602 participants · Yunlong Wang

Conditions: Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFpEF), Tirzepatide

No results postedNCT07630454

A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants

PHASE2

Status: Not Yet Recruiting · 60 participants · Shanghai Zhongshan Hospital

Conditions: Obesity Adult Onset

No results postedNCT07671391

Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer

PHASE2

Status: Not Yet Recruiting · 40 participants · UNC Lineberger Comprehensive Cancer Center

Conditions: Endometrial Cancer, Endometrial Intraepithelial Neoplasia, Grade 1 Endometrial Endometrioid Carcinoma

No results postedNCT07078838

AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes

PHASE4

Status: Not Yet Recruiting · 285 participants · The First Affiliated Hospital of Anhui Medical University

Conditions: Obesity, Diabetes Mellitus, Type 2

No results postedNCT07697391

Tirzepatide for the Treatment of Cannabis Use Disorder

PHASE2

Status: Not Yet Recruiting · 6 participants · Brigham and Women's Hospital

Conditions: Cannabis Use Disorder

No results postedNCT07265752

Preoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass Surgery

N/A

Status: Not Yet Recruiting · 96 participants · Mario Musella MD

Conditions: Obesity (BMI > 35) and Diabetes Mellitus, Obesity (BMI > 35) and Dyslipemia, Obesity (BMI > 35) and High Blood Pressure

No results postedNCT07622992

Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes

PHASE2

Status: Not Yet Recruiting · 44 participants · Victor Chang Cardiac Research Institute

Conditions: Type 1 Diabetes Mellitus

No results postedNCT06820281

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

PHASE4

Status: Recruiting · 30 participants · Weill Medical College of Cornell University

Conditions: Obesity (Disorder), Breast Cancer

No results postedNCT07257484

Incretin Therapies in Obesity-related HFpEF

PHASE4

Status: Not Yet Recruiting · 50 participants · Columbia University

Conditions: Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity

No results postedNCT07554638

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

PHASE2

Status: Recruiting · 204 participants · Regeneron Pharmaceuticals

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

No results postedNCT07527910

Adverse event reports (FDA FAERS)

product tampering408
nausea327
vomiting279
diarrhoea231
fatigue132
constipation130
off label use120
drug interaction104
headache90
drug ineffective88

FDA FAERS spontaneous reports. A report is not proof the substance caused the event, and an absence of reports is not evidence of safety.

Source: ClinicalTrials.gov and openFDA. Updated automatically.

Looking for Tirzepatide?

Source research-grade Tirzepatide from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Questions to ask a qualified clinician about Tirzepatide

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Am I eligible for NHS access to tirzepatide for my situation?
What is the dose-titration plan and how will side effects be monitored?
How do you confirm the product I receive is genuine Mounjaro?
What is the plan if I want to come off the medicine?
How should I report a suspected side effect?

Is tirzepatide a peptide, and what is its status in the UK?

What are the key facts about Tirzepatide?

Quick Facts

Overview

01Evidence snapshot

02Human evidence grade

03Preclinical evidence grade

04Regulatory status

05Approved medical uses

06Unapproved / promotional claims

07Common internet claims

08Claim vs evidence

09Safety uncertainty score

10Known adverse signals

11Drug-interaction uncertainty

12Anti-doping status

13UK legal position

14EU legal position

15What this page cannot tell you

16Last reviewed

17Citation quality score

18Research gaps

19Safer alternatives / established care pathways

20Doctor discussion prompts

Questions to ask a qualified clinician

Discovery & History

Mechanism of Action

Researched Benefits

Claim vs Evidence

Theoretical Dosing & Protocols

Administration Routes

Safety Profile & Known Risks

Commonly Reported Side Effects

Rare Risks & Concerns

Contraindications

UK & EU Regulatory Context

🇬🇧 United Kingdom

🇪🇺 European Union

Clinical Studies Summary

SURMOUNT-1: Tirzepatide for Weight Management

SURPASS-2: Tirzepatide vs Semaglutide

SURMOUNT-3: After Lifestyle Intervention

SURMOUNT-4: Weight Maintenance

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.

Registered Trials & Regulatory Status

Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF

A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants

Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer

AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes

Tirzepatide for the Treatment of Cannabis Use Disorder

Preoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass Surgery

Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

Incretin Therapies in Obesity-related HFpEF

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

Adverse event reports (FDA FAERS)

Looking for Tirzepatide?

Frequently Asked Questions